Eli Lilly to Challenge $20 Million Cialis Patent Verdict

Eli Lilly and Co. is looking to overturn a $20 million verdict finding it infringed a patent by selling its famous Cialis erectile dysfunction drug as a treatment for enlarged prostate (Erfindergemeinschaft UroPep Gbr v. Eli Lilly and Co., Fed. Cir., No. 15-cv-1202, notice of appeal filed, 9/25/17).

In April, a jury awarded Erfindergemeinschaft UroPep Gbr $20 million in damages after finding Eli Lilly infringed UroPep’s U.S. Patent No. 8,791,124. UroPep asserted in a U.S. District Court for the Eastern District of Texas trial Eli Lilly infringed the patent by marketing and selling Cialis ...